Acadia Pharma (ACAD) Misses Q1 EPS by 7c, Revs Beat
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.38 -3.9%
EPS Growth %: -52.4%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -52.4%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $62.96 million versus the consensus estimate of $60.69 million.
GUIDANCE:
Acadia Pharma sees FY2019 revenue of $280-300 million, versus the consensus of $291.2 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Aytu BioScience (AYTU) Tops Q4 EPS by 28c
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
